Shenzhen-based Axbio on Monday announced the completion of a Series B funding round at close to $100 million as the startup looks to advance its next-generation sequencing technology and build its first good manufacturing practice (GMP) factory.
Start your deal-making journey now!
Subscribe now to enjoy unlimited access at just $59.
Premium coverage on private equity, venture capital, and startups in Asia.
Exclusive scoops from our reporters in nine key markets.
In-depth interviews with industry leaders shaping the ecosystem.
Already a Subscriber? Log in
Contact us for corporate subscriptions at subs@dealstreetasia.com
